Chart-Typ:
Zeitraum:
| Paragon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up | WASHINGTON (dpa-AFX) - Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed... ► Artikel lesen |
| Morning Market Movers: BIO-key International, Alaunos Therapeutics, Fitness Champs, Linkers Industries See Big Swings | BEIJING (dpa-AFX) - At 8:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| Alaunos Therapeutics, Inc.: Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study | This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery | New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results New QIAGEN Discovery Platform extends AI into drug... ► Artikel lesen |
| Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.